Retatrutide is a novel therapeutic/treatment/medicine agent under investigation for the management/treatment/control of type 2 diabetes. It belongs to a class of drugs known as GLP-1 receptor agonists/glucagon-like peptide-1 receptor agonists/glucose-dependent trizept insulinotropic polypeptide agonists, which work by stimulating/activating/enhanci

Arriving in the landscape of obesity management, retatrutide represents a unique strategy. Different from many existing medications, retatrutide works as a double agonist, at once targeting both glucagon-like peptide-1 (GLP-1) and glucose-sensitive insulinotropic polypeptide (GIP) sensors. The simultaneous activation encourages various helpful effe